Advertisement

Topics

Mateon’s ovarian cancer treatment CA4P shows favorable results in Focus study

02:27 EDT 17 Aug 2017 | Pharmaceutical Business Review

Mateon Therapeutics’ ovarian cancer treatment CA4P in combination with Roche’s bevacizumab (Avastin) has showed favorable results in the scheduled interim analysis of the ongoing phase 2/3 Focus study.

Original Article: Mateon’s ovarian cancer treatment CA4P shows favorable results in Focus study

NEXT ARTICLE

More From BioPortfolio on "Mateon’s ovarian cancer treatment CA4P shows favorable results in Focus study"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...